Uric acid metabolism from Harrison for 10 marks question f

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I now have everything needed for a comprehensive 10-mark answer. Here is the full answer based directly on Harrison's Principles of Internal Medicine, 22nd Edition (2025):

Uric Acid Metabolism

(Harrison's Principles of Internal Medicine, 22nd Ed — Chapter 384)

1. End Product of Purine Metabolism

Uric acid is the final catabolic end product of purine metabolism in humans. At physiologic pH (7.4), it exists predominantly as urate (the ionized form), given its weak acidic property (pKa = 5.8). This is unique to humans: most other mammals possess uricase (urate oxidase), which converts urate into the highly water-soluble compound allantoin. Humans (and some higher primates) have an evolutionary loss of functional uricase, making them uniquely susceptible to hyperuricemia and gout.

2. Pathways of Urate Production

Urate production pathways — de novo synthesis and salvage pathways (Harrison's Fig. 384-2)

There are two main routes through which purines are synthesised, ultimately yielding urate:

A. De Novo Synthesis

Starts with Ribose-5-phosphate + ATP, converted by PRPP synthetase (PRS) to 5-phosphoribosyl-1-pyrophosphate (PRPP)
PRPP is the key branch-point substrate funnelled into the purine ring synthesis pathway
End products of the pathway are AMP, IMP, and GMP (purine nucleotides)
These are degraded sequentially to nucleosides → free bases (hypoxanthine, guanine) → xanthine → urate via xanthine oxidase

B. Salvage Pathway

Free purine bases released from tissue nucleic acid turnover are "salvaged" (recycled) back to nucleotides
HPRT (hypoxanthine-guanine phosphoribosyltransferase) salvages:
- Hypoxanthine → Inosine monophosphate (IMP)
- Guanine → Guanosine monophosphate (GMP)
APRT (adenine phosphoribosyltransferase) salvages adenine → AMP
The salvage pathway reduces net urate production by recycling purines — its failure (HPRT deficiency) leads to overproduction

C. Final Steps — Xanthine Oxidase

Hypoxanthine → Xanthine (via xanthine oxidase)
Xanthine → Urate (via xanthine oxidase)
Guanine is also converted to xanthine via guanine deaminase
Allopurinol and febuxostat inhibit xanthine oxidase, blocking the final steps

3. Regulation and Feedback

IMP, AMP, and GMP provide feedback inhibition of PRPP synthetase and the de novo pathway, controlling the rate of purine synthesis
When HPRT is absent or deficient (as in Lesch-Nyhan syndrome), salvage is lost → PRPP is not consumed in the salvage pathway → PRPP accumulates → drives de novo synthesis → massive urate overproduction

4. Causes of Urate Overproduction

Mechanism	Example
PRPP synthetase superactivity	X-linked inborn error; leads to ↑PRPP → ↑purine nucleotides → ↑urate
HPRT deficiency (partial)	Kelley-Seegmiller syndrome → gout + urate nephropathy
HPRT deficiency (complete)	Lesch-Nyhan syndrome → self-mutilation + hyperuricemia
↑ATP degradation to AMP → urate	Alcohol (↑NAD reduction), fructose ingestion, glycogen storage diseases (Types I, III, V, VIII), severe tissue hypoxia
Increased cell turnover	Myeloproliferative disorders, psoriasis, hemolytic anemia, cytotoxic therapy

5. Urate Excretion

The systemic urate concentration reflects a balance between dietary intake, endogenous synthesis, and excretion:

~2/3 of daily uric acid is eliminated via the kidney (renal excretion)
~1/3 via the gastrointestinal tract (intestinal uricolysis by gut bacteria)

Renal Handling (Proximal Tubule)

A four-component model operates in the proximal tubule:

Filtration at glomerulus
Near-complete reabsorption (~98–99%) early proximal tubule
Secretion mid-proximal tubule
Post-secretory reabsorption

Key transporters:

URAT1 and OAT10 (apical membrane) — mediate urate reabsorption via sodium-coupled anion exchange; inhibited by uricosuric drugs (probenecid, losartan, SGLT2 inhibitors)
GLUT9 (basolateral membrane) — exits urate into interstitium
ABCG2 — high-capacity urate efflux transporter in renal proximal tubule AND intestinal epithelium; genetic variants are the most common cause of impaired extra-renal urate excretion

Anti-uricosuric agents (e.g., pyrazinoate, nicotinate, low-dose aspirin) promote urate reabsorption via these transporters, raising serum urate.

6. Hyperuricemia: Mechanisms

Hyperuricemia (serum urate >6.85 mg/dL) arises from:

Impaired renal excretion — accounts for ~90% of cases (diuretics, CKD, lead nephropathy, cyclosporine)
Overproduction — ~10% (inborn errors, myeloproliferative disorders, high purine diet)
Combined mechanisms — most cases of clinical gout

7. Pathogenesis of Gout from Hyperuricemia

Pathogenesis of gout and therapeutic targets (Harrison's Fig. 384-1)

Chronic hyperuricemia → supersaturation → monosodium urate (MSU) crystal deposition in joints and connective tissue → phagocytosis by neutrophils → NLRP3 inflammasome activation → IL-1β, IL-6, TNF-α release → acute gouty arthritis. Persistent crystal deposition leads to tophi and chronic gouty arthritis.

8. Normal Values and Measurement

Serum uric acid: 238–516 μmol/L (4.0–8.7 mg/dL) by uricase method
Useful to diagnose gout and monitor urate-lowering therapy (target: <5–6 mg/dL for dissolution of crystals)

Summary Table

Step	Enzyme / Transporter	Clinical Relevance
De novo PRPP synthesis	PRPP synthetase	Superactivity → ↑urate
Salvage of hypoxanthine/guanine	HPRT	Deficiency → Lesch-Nyhan; ↑urate
Hypoxanthine → Xanthine → Urate	Xanthine oxidase	Target of allopurinol, febuxostat
Renal reabsorption	URAT1, OAT10	Target of probenecid, SGLT2i
Basolateral exit	GLUT9	Key transporter
Intestinal excretion	ABCG2	Variants → underexcretion gout

— Harrison's Principles of Internal Medicine, 22nd Edition (2025), Chapter 384: Crystal-Induced Arthropathies

Aerobic glycolysis from Harrison and standard biochemistry harperfor 10 marks question and answer with relevant good flowcharts for final yr pg general medicine

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I now have all three textbook sources and the key diagrams. Let me compile the complete 10-mark answer:

Aerobic Glycolysis — 10 Mark Answer

(Sources: Harper's Illustrated Biochemistry 32nd Ed, Basic Medical Biochemistry 6th Ed, Harrison's Principles of Internal Medicine 22nd Ed)

1. Definition and Significance

Aerobic glycolysis is the cytosolic, oxygen-dependent pathway in which one molecule of glucose (6-carbon) is oxidized to two molecules of pyruvate (3-carbon each), generating ATP, NADH, and biosynthetic precursors, with oxygen required to reoxidize the NADH produced.

Location: Cytosol (all enzymes are cytosolic)
Glucose is the universal fuel for human cells — the brain uses it almost exclusively; after a high-carbohydrate meal, glucose is the major fuel for all tissues
Aerobic glycolysis sets the stage for complete oxidation via the TCA cycle + oxidative phosphorylation, yielding ~30–32 mol ATP per mol glucose

2. Two Phases of Glycolysis

Phases of glycolysis: preparative and ATP-generating (Basic Medical Biochemistry, Fig. 22.4)

Phase	Description	ATP change
Phase I — Preparatory ("priming")	Glucose → Fructose-1,6-bisphosphate	−2 ATP (invested)
Phase II — ATP-generating	2× Triose phosphate → 2× Pyruvate	+4 ATP + 2 NADH
Net		+2 ATP + 2 NADH

3. The 10 Reactions of Glycolysis (Harper's Fig. 17-2)

Complete glycolytic pathway — all 10 reactions with enzymes (Harper's Fig. 17-2)

Phase I — Preparatory Phase (Reactions 1–5)

Step	Reaction	Enzyme	Notes
1	Glucose → Glucose-6-phosphate (G6P)	Hexokinase (all tissues) / Glucokinase (liver, pancreatic β-cells)	ATP consumed; irreversible; HK inhibited by G6P; GK not inhibited by G6P, high Km
2	G6P → Fructose-6-phosphate (F6P)	Phosphoglucose isomerase	Reversible; isomerization
3	F6P → Fructose-1,6-bisphosphate (F1,6-BP)	Phosphofructokinase-1 (PFK-1)	ATP consumed; rate-limiting, committed step; irreversible
4	F1,6-BP → DHAP + Glyceraldehyde-3-phosphate (G3P)	Aldolase	Cleavage of 6C → two 3C molecules
5	DHAP ⇌ G3P	Triose phosphate isomerase	Equilibrium; DHAP converted to G3P for further metabolism

From this point, all reactions occur twice (×2) per glucose

Phase II — ATP-Generating Phase (Reactions 6–10)

Step	Reaction	Enzyme	Notes
6	G3P + NAD⁺ + Pi → 1,3-Bisphosphoglycerate (1,3-BPG)	G3P dehydrogenase	Generates 2 NADH; high-energy acyl-phosphate bond formed; inhibited by arsenate
7	1,3-BPG + ADP → 3-Phosphoglycerate (3-PG) + ATP	Phosphoglycerate kinase	Substrate-level phosphorylation (2 ATP); "pays back" the investment
8	3-PG → 2-Phosphoglycerate (2-PG)	Phosphoglycerate mutase	Phosphate shifted from C3→C2
9	2-PG → Phosphoenolpyruvate (PEP)	Enolase	Dehydration; generates high-energy enol-phosphate; inhibited by fluoride
10	PEP + ADP → Pyruvate + ATP	Pyruvate kinase	Substrate-level phosphorylation (2 ATP); irreversible; inhibited by ATP, alanine; activated by F1,6-BP (feedforward)

4. Summary: Overall Equation

Aerobic glycolysis:

Glucose + 2 NAD⁺ + 2 Pi + 2 ADP → 2 Pyruvate + 2 NADH + 2 H⁺ + 2 ATP + 2 H₂O

ΔG°' ≈ −22 kcal/mol (pathway is overall irreversible)

5. Fate of Pyruvate Under Aerobic Conditions

Summary of glycolysis — aerobic vs. anaerobic fate (Harper's Fig. 17-1)

Under aerobic conditions, pyruvate enters the mitochondrial matrix via a proton symporter and undergoes oxidative decarboxylation by the pyruvate dehydrogenase complex (PDC):

Pyruvate + CoA + NAD⁺ → Acetyl-CoA + CO₂ + NADH

Acetyl-CoA then enters the TCA (Krebs) cycle → generating 3 NADH + 1 FADH₂ + 1 GTP per turn (×2 per glucose).

The NADH and FADH₂ are reoxidized by the electron transport chain (ETC) via oxidative phosphorylation, generating the bulk of ATP.

6. Total ATP Yield from Complete Aerobic Oxidation

(Harper's Table 17-1)

Stage	Reaction	Coenzyme / Product	ATP yield
Glycolysis	G3P dehydrogenase	2 NADH (cytosolic)	5 (via malate-aspartate shuttle)
Glycolysis	Phosphoglycerate kinase	Substrate-level	2
Glycolysis	Pyruvate kinase	Substrate-level	2
Glycolysis	Hexokinase + PFK-1	ATP consumed	−2
Glycolysis net			7
Pyruvate DH	2× Pyruvate → Acetyl-CoA	2 NADH	5
TCA	Isocitrate DH	2 NADH	5
TCA	α-KG DH	2 NADH	5
TCA	Succinate thiokinase	2 GTP	2
TCA	Succinate DH	2 FADH₂	3
TCA	Malate DH	2 NADH	5
TCA net			25
TOTAL			~30–32 ATP

Note: If the glycerophosphate shuttle (not malate-aspartate) is used for cytosolic NADH, yield = ~30 ATP. The glycerophosphate shuttle yields only 1.5 ATP/NADH vs 2.5 for malate-aspartate.

7. Regulation of Glycolysis — Three Irreversible Steps

Three enzymes catalyze physiologically irreversible (non-equilibrium) reactions — these are the major regulatory points (Harper's):

① Hexokinase / Glucokinase (Step 1)

HK: Allosterically inhibited by G6P (product inhibition) → prevents glucose accumulation → found in muscle/brain
GK (liver/β-cell): High Km, not inhibited by G6P; acts as a "glucose sensor"; induced by insulin; found in the nucleus bound to glucokinase regulatory protein in the fasted state

② Phosphofructokinase-1 — PFK-1 (Step 3) — Rate-limiting step

Activators	Inhibitors
AMP, ADP	ATP (allosteric)
Fructose-2,6-bisphosphate (F2,6-BP) — most potent activator	Citrate
Pi	Low pH

F2,6-BP is the principal regulator in liver: insulin ↑ F2,6-BP (via PFK-2 activation) → stimulates glycolysis; glucagon ↓ F2,6-BP → inhibits glycolysis, promotes gluconeogenesis

③ Pyruvate Kinase (Step 10)

Inhibited by: ATP, acetyl-CoA, alanine (signals of energy/nutrient sufficiency)
Activated by: Fructose-1,6-bisphosphate (feedforward activation — when PFK-1 is active, PK is primed)
Liver PK (L-type): Additionally regulated by hormones via phosphorylation (glucagon → cAMP → PKA → phosphorylates PK → inhibits it; insulin dephosphorylates → activates it)

8. NADH Shuttle Systems (Critical for Aerobic ATP Yield)

NADH cannot cross the inner mitochondrial membrane. Two shuttles transfer its reducing equivalents:

Shuttle	Tissues	Mitochondrial acceptor	ATP per NADH
Malate-aspartate shuttle	Heart, liver, kidney	NAD⁺ → NADH	2.5 ATP
Glycerophosphate shuttle	Brain, skeletal muscle, white fat	FAD → FADH₂	1.5 ATP

9. Aerobic vs. Anaerobic Glycolysis — Comparison

Feature	Aerobic Glycolysis	Anaerobic Glycolysis
O₂ required?	Yes (to reoxidize cytosolic NADH)	No
End product	Pyruvate → Acetyl-CoA → TCA	Lactate (via LDH)
ATP yield	~30–32 ATP/glucose	2 ATP/glucose
NADH fate	Enters ETC via shuttles	Reoxidized by pyruvate → lactate
Tissues	Most aerobic tissues (heart, liver, brain)	RBC (no mitochondria), renal medulla, WBCs, exercising muscle
NAD⁺ regeneration	Via ETC	Via lactate dehydrogenase (LDH)

10. Clinical Relevance (Harrison's, 22nd Ed)

Condition	Mechanism	Result
Lactic acidosis	Hypoxia → O₂ unavailable → anaerobic glycolysis → lactate accumulates, exceeds buffer capacity	↓ pH, lactic acidemia
Warburg effect (cancer)	Tumours preferentially use aerobic glycolysis → lactate even with O₂ ("aerobic glycolysis")	Basis of PET imaging (↑¹⁸F-FDG uptake)
Thiamine (B₁) deficiency	Pyruvate dehydrogenase (requires TPP) impaired → pyruvate accumulates → lactic acidosis	Wernicke's encephalopathy, beriberi
G6PD deficiency	G6P cannot enter pentose phosphate pathway → oxidative stress in RBCs	Haemolytic anaemia
Brain hypoxia	Neurons rely on aerobic glucose oxidation for ATP; O₂ interruption → consciousness lost within 10 seconds	Ischaemic stroke, cardiac arrest
Glycogen storage diseases (Types I, III, V, VIII)	Inability to mobilize glucose → impaired glycolysis during fasting/exercise	Fasting hypoglycaemia, exercise intolerance
Arsenate poisoning	Arsenate substitutes for Pi in reaction 6 → forms 1-arseno-3-phosphoglycerate (unstable) → bypasses ATP generation at step 7	Loss of ATP generation from glycolysis
Fluoride poisoning	Inhibits enolase (step 9)	Blocks glycolysis
2,3-BPG in RBCs	Bypass of phosphoglycerate kinase step → 2,3-BPG formed → binds Hb → ↓ O₂ affinity	Adaptation to hypoxia; impaired in hexokinase deficiency

Flowchart Summary

GLUCOSE (C₆)
    │ ATP ──── Hexokinase / Glucokinase [Step 1] ← Inhibited by G6P (HK)
    ▼
Glucose-6-Phosphate
    │ ──── Phosphoglucose isomerase [Step 2]
    ▼
Fructose-6-Phosphate
    │ ATP ──── PFK-1 [Step 3] ← RATE-LIMITING; activated by AMP, F2,6-BP
    ▼                                              inhibited by ATP, citrate
Fructose-1,6-Bisphosphate
    │ ──── Aldolase [Step 4]
    ├──────────────────────────┐
    ▼                          ▼
Glyceraldehyde-3-P ←────── DHAP [Triose phosphate isomerase, Step 5]
×2 below ↓
    │ NAD⁺→NADH ──── G3P Dehydrogenase [Step 6]  ← 2 NADH generated
    ▼
1,3-Bisphosphoglycerate
    │ ADP→ATP ──── Phosphoglycerate Kinase [Step 7] ← 2 ATP (substrate-level)
    ▼
3-Phosphoglycerate
    │ ──── Phosphoglycerate mutase [Step 8]
    ▼
2-Phosphoglycerate
    │ ──── Enolase [Step 9] ← Inhibited by fluoride
    ▼
Phosphoenolpyruvate (PEP)
    │ ADP→ATP ──── Pyruvate Kinase [Step 10] ← 2 ATP; activated by F1,6-BP
    ▼
PYRUVATE (×2)
    │
    ├─ [AEROBIC: O₂ present] ──→ PDC → ACETYL-CoA → TCA cycle → ETC → ~30-32 ATP total
    │
    └─ [ANAEROBIC: no O₂] ───→ LDH → LACTATE + NAD⁺ (regenerated) → 2 ATP total

Sources: Harper's Illustrated Biochemistry 32nd Ed (Ch. 17); Basic Medical Biochemistry: A Clinical Approach 6th Ed (Ch. 22); Harrison's Principles of Internal Medicine 22nd Ed (2025)

This is a shared conversation. Sign in to Orris to start your own chat.